|Bid||120.00 x 800|
|Ask||199.68 x 800|
|Day's range||150.09 - 158.00|
|52-week range||137.21 - 327.32|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||61.10|
|Earnings date||25 July 2022 - 29 July 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||239.88|
Moderna (NASDAQ: MRNA) and Repligen (NASDAQ: RGEN) are two companies that have seen their stock prices decrease even as they posted positive business results. While Moderna may have been known to some investors prior to the pandemic, the biotech company has become a household name as it was able to bring to market its highly successful vaccine for COVID-19. Prior to this, Moderna had nothing commercially available, so the sales growth over the past year-plus is from a base of zero revenue.
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...